Overview
- Laboratory analysis confirmed the supplement contained sildenafil in doses sufficient to alter physiological functions.
- The presence of an active pharmaceutical ingredient legally reclassifies the product as a medicinal product requiring prior approval.
- AEMPS has prohibited further sales and instructed distributors to withdraw all existing stock from the Spanish market.
- Officials warn that undisclosed sildenafil can cause cardiovascular reactions such as heart attack, stroke and fatal arrhythmias.
- Labeling falsely promoted vitamins and minerals, misleading consumers about the product’s true composition.